Central Nervous System
If it’s your first time on this website, please read the disclaimer section.
Jun 01 – Jun 08, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 1 trial evaluated ABBV-706, a SEZ6-targeting antibody-drug conjugate, in 288 patients with advanced solid tumors, specifically focusing on relapsed/refractory small cell lung cancer (R/R SCLC). In the R/R SCLC cohort, the objective response rate was 52%, with a median overall survival of 12.4 months at the 1.8 mg/kg dose. Safety data showed grade 3 or higher treatment-related adverse events in 61% of patients, primarily anemia and fatigue, which were dose-dependent. These findings establish 1.8 mg/kg every three weeks as the recommended phase 2 dose, offering a promising new therapeutic strategy for neuroendocrine-derived cancers.
10.1038/s41591-026-04452-0
May 25 – Jun 01, 2026
Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This national cohort study assessed longitudinal risks and methods for suicidal self-directed violence (SSDV) among 292,271 veterans with invasive solid or hematologic cancer (2014-2023) using registries. Overall, 2400 SSDV events occurred (203 per 100,000 person-years), with poisoning most common (26%). High rates were found in patients with CNS, pancreas, head and neck, liver and biliary system, and thyroid cancers, advanced cancer (261 per 100,000 person-years), severe frailty, chronic mental illness, and high pain scores. Risks persisted five years post-diagnosis for younger (≤45 years), unmarried, advanced cancer, and CNS cancer patients, highlighting vulnerable subgroups. This emphasizes the critical need for systematic tracking of suicidal behaviors and tailored screening strategies within comprehensive cancer care, especially for these high-risk populations.
10.1001/jamaoncol.2026.1459
Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase II trial evaluated a risk-adapted management strategy for WHO grade 1-3 meningioma, utilizing observation for low-risk patients and specific radiotherapy doses (54 Gy or 60 Gy) for intermediate- and high-risk cohorts. At a 12-year median follow-up, 10-year progression-free survival rates were 85.2% for low-risk, 72.2% for intermediate-risk, and 42.5% for high-risk groups, while overall survival reached 94.1%, 84.7%, and 51.1%, respectively. The study demonstrates that observation is viable for low-risk tumors, while radiotherapy provides structured control for more aggressive grades, despite grade 3+ toxicities occurring in up to 15.1% of high-risk patients. These long-term results establish definitive benchmarks for meningioma management and validate risk-stratification protocols in neuro-oncology practice.
10.1200/JCO-25-01441
May 18 – May 25, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study reanalyzed three experimental arms of the INSIGhT platform trial for newly diagnosed glioblastoma by comparing internal control data with propensity score-matched external control data from real-world and clinical sources. Results showed no survival benefit for abemaciclib (HR 1.00; 95% CI, 0.75–1.34), neratinib (HR 0.93; 95% CI, 0.70–1.24), or CC-115 (HR 0.88; 95% CI, 0.41–1.88), which mirrored the original trial’s internal control findings. For clinicians treating glioblastoma, the study demonstrates that carefully matched external controls can produce reliable treatment effect estimates in early-phase testing of experimental therapies. These findings suggest that hybrid randomized designs leveraging external data may accelerate oncology drug development, provided comprehensive data on potential confounders are available to mitigate bias.
10.1200/JCO-25-01586
May 11 – May 18, 2026
MRI-guided adaptive radiotherapy for high grade glioma (UNITED): a single-centre, single-arm, non-inferiority, phase 2 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This phase 2 trial evaluated the safety of a small-margin (5 mm), MRI-guided adaptive radiotherapy approach using a 1.5 T MR-Linac for 98 patients with glioblastoma. The primary outcome demonstrated a marginal failure risk of only 4% (95% CI 0–8), successfully meeting non-inferiority criteria compared to historical controls using larger margins. By utilizing weekly gadolinium-enhanced online adaptation, clinicians can significantly reduce the volume of irradiated healthy brain tissue without increasing the risk of local recurrence. These results support the feasibility of margin de-escalation in high-grade glioma treatment, potentially reducing treatment-related toxicity while maintaining oncological control.
10.1016/S1470-2045(26)00088-4
Apr 13 – Apr 20, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase II/III Bayesian adaptive platform trial (GBM AGILE) evaluated the efficacy of regorafenib, a multikinase inhibitor, against standard-of-care controls in patients with newly diagnosed unmethylated (NDU) and recurrent (RD) glioblastoma. The study found no improvement in overall survival (OS) for regorafenib, with median hazard ratios of 1.05 for NDU and 1.07 for RD, and low final probabilities of benefit at 0.421 and 0.312, respectively. Clinically, regorafenib was associated with increased toxicity compared to control treatments, leading to its removal from National Comprehensive Cancer Network (NCCN) guidelines for recurrent disease. These results demonstrate that regorafenib is not superior to current standards of care for glioblastoma and highlight the utility of adaptive platform trials in efficiently evaluating oncology therapeutics.
10.1200/JCO-25-01137
Multidisciplinary management of meningiomas in the era of precision oncology.
NAT REV CLIN ONCOL · Q1 JOURNAL - RANK #2/326TOP-TIER
This comprehensive review evaluates the transition from traditional histopathology-based WHO grading to molecularly driven classification for the management of meningiomas, the most common primary intracranial tumor. The authors highlight how precision tools, including somatostatin receptor-targeted PET-CT and targeted systemic agents like immune checkpoint inhibitors, are redefining treatment paradigms beyond standard surgery and radiotherapy. For the oncology-focused clinician, the study provides a roadmap for integrating predictive biomarkers and personalized therapeutic strategies into multidisciplinary care. The primary implication is that standardizing these molecular frameworks is essential for optimizing clinical trial designs and improving outcomes in neuro-oncological practice.
10.1038/s41571-026-01148-9
Mar 02 – Mar 09, 2026
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This Phase II clinical trial investigated a triple combination therapy of adebrelimab, bevacizumab, and cisplatin/carboplatin in 35 patients with triple-negative breast cancer (TNBC) and active brain metastases. The study reported a confirmed CNS objective response rate of 77.1% (27/35) and a CNS clinical benefit rate of 80.0% (28/35), with a median CNS-PFS of 10.3 months and median OS of 21.1 months. These findings demonstrate promising intracranial antitumor activity and prolonged survival outcomes for a highly lethal form of cancer, directly addressing a critical need in oncology. The regimen shows a manageable safety profile and warrants further investigation as a potential new treatment option for TNBC patients with brain metastases.
10.1200/JCO-25-02021